Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization

International Review of Law and Economics

Volumn 32, Issue 1, 2012, Pages 95-109

  Duflos, Gautier ^a,b   Lichtenberg, Frank R ^c,d  

^a UNIVERSITÉ PARIS 1 PANTHÉON SORBONNE   (France)

^b PARIS SCHOOL OF ECONOMICS   (France)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

Competition; Drug prices; Generic drugs; Marketing; Patent; Pharmaceutical

Indexed keywords

EID: 84859267668     PISSN: 01448188     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.irle.2011.08.003     Document Type: Article

References (32)

1. Berenson, A. (2006). Merck Loses Protection for Patent on Zocor. New York Times, June 23,.
2. Berndt, E. R., Kyle, M., & Ling, D. (2003). The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches (pp. 229-274), in Scanner Data and Price Indexes, National Bureau of Economic Research.
3. Canadian Institute for Health Information, Drug Expenditure in Canada, 1985 to 2007 (Ottawa: CIHI, 2008). http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_page=download_form_e&cw_sku=DRUGEXP8507ENPDF&cw_ctt=1&cw_dform=N.
4. Chartrand, S. (1999). Patents; A Supreme Court decision leaves many innovators disgusted, angry and outraged. New York Times, June 28, http://www.nytimes.com/1999/06/28/business/patents-supreme-court-decision-leaves-many-innovators-disgusted-angry-outraged.html?scp=4%26sq=patents%20supreme%20court%26st=cse.
5. Ching, A. T. (2004). Some observations in the US prescription drug market after patent expiration during the 80s. Working paper, Rotman School of Management. Available at SSRN: http://ssrn.com/abstract=1492264.
6. Ching A.T. Consumer learning and heterogeneity: Dynamics of demand for prescription drugs after patent expiration. International Journal of Industrial Organization 2010, 28(6):619-638.
7. Ching A.T. A dynamic oligopoly structural model for the prescription drug market after patent expiration. International Economic Review 2010, 51(4):1175-1207.
8. National Health Expenditure Web Tables, http://www.cms.hhs.gov/NationalHealthExpendData/downloads/tables.pdf.
9. Congressional Budget Office. (1998). How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry, July, http://www.cbo.gov/showdoc.cfm?index=655%26sequence=0.
10. Caves R.E., Whinston M.D., Hurwitz M.A., Pakes A., Temin P. Patent expiration, entry, and competition in the U.S. Pharmaceutical Industry. Brookings Papers on Economic Activity, Microeconomics 1991, 1991:1-66.
11. Dorfman R., Steiner P.O. Optimal advertising and optimal quality. The American Economic Review 1954, 44:826-836.
12. Ellison G., Ellison G. Strategic entry deterrence and the behavior of pharmaceutical incumbents prior to patent expiration. American Economic Journal: Microeconomics 2011, 3(1):1-36.
13. Frank R.G., Salkever D.S. Generic entry and the pricing of pharmaceuticals. Journal of Economics & Management Strategy 1997, 6(1):75-90.
14. Gagnon M.-A., Lexchin J. The Cost of Pushing Pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine 2008, 5(1):e1. 10.1371/journal.pmed.0050001.
15. Grabowski H.G., Vernon J.M. Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics 1992 October, 35(2):331-350.
16. Glover G.J. The influence of market exclusivity on drug availability and medical innovations. AAPS Journal 2007, 9(3). Available online: http://www.aapsj.org/view.asp?art=aapsj0903034.
17. Graham, S. J. H., & Higgins, M. J. (2006). The impact of patenting on new product development in the pharmaceutical industry, working paper, Georgia Institute of Technology, http://mgt.gatech.edu/news_room/news/2006/reer/files/reer_impact_of_patenting.pdf.
18. Greenhouse, L. (2007), " High Court Puts Limits on Patents" New York Times, May 1, http://www.nytimes.com/2007/05/01/business/01bizcourt.html?scp=6%26sq=patents%20supreme%20court%26st=cse.
19. Guido, I., & Lemieux, T. (2007). Regression discontinuity designs: a guide to practice. NBER Technical Working Paper, No. 337, April 2007.
20. Drugs and health: economic issues and policy objectives 1981, American Enterprise Institute for Public Policy Research, Washington, DC. R.B. Helms (Ed.).
21. Lakdawalla, D., Philipson, T., & Wang, Y. R. (2006). Intellectual property and marketing. NBER Working Paper No. 12577.
22. Lichtenberg F., Sun S. The impact of Medicare Part D on prescription drug use by the elderly: evidence from a large retail pharmacy chain. Health Affairs 2007 November/December, 26(6):1735-1744.
23. Ma J., Stafford R.S., Cockburn I.M., Finkelstein S.N. A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998. Clinical Therapeutics 2003, 25(May (5)):1503-1517. http://www.cci.som.yale.edu/events/documents/Presentation-YCCI-SridharNarayanan.ppt.
24. Pindyck R., Rubinfeld D. Microeconomics 2009, Pearson Prentice Hall, Upper Saddle River, NJ. 7th ed.
25. Regan Tracy L. Generic entry, price competition, and market segmentation in the prescription drug market. International Journal of Industrial Organization 2008 July, 26(4):930-948.
26. Rosenthal M.B., Berndt E.R., Donohue J.M., Frank R.G., Epstein A.M. Promotion of prescription drugs to consumers. New England Journal of Medicine 2002 Feb 14, 346(7):498-505.
27. Rubin, R. (2002). Claritin to go OTC next spring, Clarinex to replace it. USA Today, April 22, http://www.usatoday.com/news/health/drugs/2002-04-23-claritin.htm.
28. Statman M. The Effect of Patent Expiration on the Market Position of Drugs. Drugs and health: economic issues and policy objectives 1981, 140-150. American Enterprise Institute for Public Policy Research, Washington, DC. R.B. Helms (Ed.).
29. Tirole J. The theory of industrial organization 1988, MIT Press, Cambridge.
30. Vardanyan M., Tremblay V.J. The measurement of marketing efficiency in the presence of spillovers: theory and evidence. Managerial and Decision Economics 2006, 27(5):319-331.
31. Verbeek, M., & Joop, H. (2007). Spillover Effects of Marketing in Mutual Fund Families. ERIM Report Series; EFA 2007 Ljubljana Meetings Paper, February 26. Available at SSRN: http://ssrn.com/abstract=958784.
32. Wagner T., Michele H., John P. Tiered co-payments and cost-related medication underuse?. Paper presented at the annual meeting of the Economics of Population Health: Inaugural Conference of the American Society of Health Economists 2006, http://www.allacademic.com/meta/p92398_index.html.